New Insights into Cancer Immunotherapy: From Immune Cell to Clinical Practice
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 141
Special Issue Editor
Special Issue Information
Dear Colleagues,
The landscape of cancer immunotherapy is rapidly expanding, driven by advancements in the harnessing of various immune cell types to combat cancer. This Special Issue highlights recent breakthroughs in immunotherapy, encompassing T cells, natural killer (NK) cells, dendritic cells, macrophages, myeloid-derived suppressor cells (MDSCs), and other immune components shaping anti-tumor responses. We welcome studies on engineered immune cell therapies, bispecific immune engagers, immune checkpoint modulation, and novel combination strategies for enhancing therapeutic efficacy and overcoming resistance. Additionally, contributions on tumor microenvironment interactions, mechanisms of immune evasion, and translational research connecting preclinical discoveries to clinical practice are highly encouraged. Through this Special Issue, we seek to provide comprehensive insights into the evolving field of cancer immunotherapy and its impact on patient outcomes.
Dr. Xiaotong Song
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- T cell therapy
- cancer immunotherapy
- CAR T cells
- immune checkpoint modulation
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
